Cingulate to Participate in Benzinga All Live Access Event
August 15, 2022 18:34 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution
August 11, 2022 08:30 ET
|
Lexaria Bioscience Corp.
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.” To...
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
August 11, 2022 06:45 ET
|
Cingulate Inc.
$5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension
August 09, 2022 08:30 ET
|
Lexaria Bioscience Corp.
NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+...
Liposomal Drug Delivery Devices Global Market Report 2022: Johnson and Johnson, Novartis & Gilead Sciences Among Key Players Driving 10.3% Annual Growth
August 01, 2022 06:33 ET
|
Research and Markets
Dublin, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The "Liposomal Drug Delivery Devices Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global liposomal drug...
Kansas City Business Journal Names Cingulate’s Louis G. Van Horn a 2022 Chief Financial Officer of the Year
July 25, 2022 13:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., July 25, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Global Drug Delivery Devices Market Expected to Grow to $100.1 Billion in 2026 at a CAGR of 4.5%
July 22, 2022 06:28 ET
|
Research and Markets
Dublin, July 22, 2022 (GLOBE NEWSWIRE) -- The "Global Drug Delivery Devices Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global drug delivery devices market...
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders
June 23, 2022 07:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 23, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational
June 17, 2022 12:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 17, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Global Drug Delivery Partnering Deals Terms and Agreements 2015-2022: Access to Over 1,500 Deal Records of Actual Deals by Company A-Z, Stage of Development, Deal Type, Therapy Focus, and Technology
June 13, 2022 04:13 ET
|
Research and Markets
Dublin, June 13, 2022 (GLOBE NEWSWIRE) -- The "Global Drug Delivery Partnering Terms and Agreements 2015-2022" report has been added to ResearchAndMarkets.com's offering. The Global Drug Delivery...